Looking Beyond the First Answer Towards Delivering Impact
Scientific research rarely gives a simple first answer, and real progress often comes from looking beyond setbacks to find new questions. Ipsen's Chief Business Officer shares how looking past failed hypotheses in areas like rare diseases and oncology can lead to valuable new treatments through smart partnerships and acquisitions.
Original image temporarily unavailable
Looking Beyond Setbacks
In drug development, a failed hypothesis in one disease area does not mean the underlying science is dead. For instance, data that missed expectations in treating liver diseases can sometimes point toward effective paths in primary biliary cholangitis, showing that biochemical markers can reveal hidden potential if researchers are willing to look differently.
Strategic Acquisitions and Expertise
Companies must combine deep therapeutic expertise with the courage to pursue overlooked opportunities. Ipsen's moves, such as acquiring Memo Therapeutics for kidney-related conditions and Kartos Therapeutics for oncology, highlight how complete data analysis can guide companies into new fields without starting from scratch.
The Future of Medicine
The future of healthcare will not rely on repeatedly asking the same dead-end questions. True innovation demands the discipline to follow evidence and the courage to pivot, turning unexpected scientific outcomes into meaningful therapies for patients.
View selection rationale
Importance 38/100
About this brief
- Content type
- Research summary
- Source type
- Publisher report
- Original source
- Fierce Biotech ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.